U.S. appeals court backs Gilead in ruling limiting overseas imports of its medications by alternative funding programs

A U.S. appeals court ruled in favor of Gilead Sciences in a dispute involving companies described as alternative funding programs that import Gilead medications from overseas, a decision reported by CNBC on August 14, 2026. The court’s ruling limits the ability of those firms to bring the company’s drugs into the United States through that channel, which the report says is used to support patient access efforts in the U.S.

The case centers on whether the companies could import Gilead medicines purchased abroad as part of their alternative funding model. Gilead, according to the report, argued that the companies’ overseas sourcing and import practices run contrary to legal restrictions on drug distribution and related compliance requirements.

According to CNBC, the ruling is viewed as a “blow” to alternative funding programs that rely on importing medicines from outside the U.S. supply chain to support beneficiaries. For patients and administrators who have depended on those flows, the decision creates immediate uncertainty about availability, sourcing, and whether contracts and workflows for importing will need to change.

The companies involved in the alternative funding model were seeking to preserve the overseas import pathway. The appeals court’s decision, as described in the report, rejects that effort and affirms Gilead’s position that the import practices cannot proceed as those companies were doing.

While the report focuses on Gilead’s legal victory, it also highlights the broader compliance implications for the drug access industry, where program structures can blur the line between patient assistance and distribution. Court scrutiny of import practices can affect not only the companies in the litigation, but also other entities that design patient support arrangements around cross-border medication sourcing.

The decision comes as U.S. regulators and courts continue to examine rules governing prescription drug distribution, including safeguards intended to reduce risks tied to counterfeit drugs, diversion, and products obtained outside approved channels. Against that backdrop, the reported ruling indicates heightened limits on import strategies tied to branded manufacturer products.

The next steps after an appeals court ruling typically depend on whether additional review is sought, and how program operators comply with the decision’s constraints. The report indicates the ruling will have practical effects for alternative funding programs that have relied on overseas import mechanisms to supply Gilead therapies.